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Background: The natural course of Crohn’s disease (CD), with continuing relapses and remissions, leads to
irreversible intestinal damage. Early adoption of immunomodulator therapy has been proposed in order to address
this; however, it is still uncertain whether early immunomodulator therapy could affect the natural course of the
disease in real practice. We evaluated the efficacy of such therapy on the prognosis of newly diagnosed patients
with CD.
Methods: This retrospective study included 168 patients who were newly diagnosed with CD and who started
treatment at Severance Hospital, Seoul, Korea between January 2006 and March 2013. The short- and long-term
outcomes were compared between patients treated with early immunomodulator therapy and those treated with
conventional therapy.
Results: A Kaplan-Meier analysis identified that administration of immunomodulators within 6 months after diagnosis
of CD was superior to conventional therapy in terms of clinical remission and corticosteroid-free remission rates
(P=0.043 and P=0.035). However, there was no statistical significance in the disease relapse rate between the two
groups (P=0.827). Patients with a baseline elevated CRP level were more likely to relapse (P<0.005). Drug-related
adverse events were more frequent in the early immunomodulator therapy group than in the conventional therapy
group (P=0.029).
Conclusions: Early immunomodulator therapy was more effective than conventional therapy in inducing remission,
but not in preventing relapse. Baseline high CRP level was a significant indicator of relapse.
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Crohn’s disease (CD) is a chronic inflammatory disease
with unknown etiology that can affect any part of the
gastrointestinal tract. Patients with CD have a host of
symptoms, including diarrhea, hematochezia, abdominal
pain, weight loss, and fever. The last few decades have
seen a gradual increase in the number of drugs available
for use in the treatment of CD. From a time when only
sulfasalazine/5-aminosalicylic acids, corticosteroids, and
antibiotics were used, we now have immunomodulators
such as thiopurines and methotrexate, as well as biological* Correspondence: geniushee@yuhs.ac
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unless otherwise stated.agents [1]. A step-up strategy, i.e., a progressively intensi-
fied method of treatment, is being recommended in
current guidelines for medical therapy of CD [2,3].
For mild disease, less toxic but often less efficacious
drugs are recommended, while on the other hand, more
efficacious yet potentially more toxic drugs are typically
administered to patients with severe disease or those
who are not responsive to first-line therapy. The purpose
of this strategy is to ensure therapeutic endpoints such as
induction and maintenance of clinical relief, withdrawal
from steroids, and prevention of post-operative relapse.
However, conventional treatment has not been successful
in reducing complications or the need for surgery [4].
According to several recent studies, more aggressive
treatment early in the disease may result in betterre-
sponse and remission rates [2,5,6]. However, one cohorttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been used more frequently over the last 25 years, there
was no significant decrease in the need for surgery in
patients with CD [4]. Therefore, it remains uncertain
whether early immunomodulator therapy could affect
the natural course of disease in real practice. Few studies
have focused on the effect of early immunomodulator
therapy on the natural course of CD. Accordingly, we
evaluated the efficacy of early immunomodulator ther-
apy on the prognosis of patients newly diagnosed with
CD in a clinical setting.Methods
Patients
We enrolled a total of 168 patients who were newly diag-
nosed with CD and who started treatment at Severance
Hospital, Seoul, Korea between January 2006 and March
2013. The diagnosis of CD was made according to previ-
ously established international criteria based on clinical,
endoscopic, histopathological, and radiological findings
[7]. The disease extent was determined through endo-
scopic and/or radiological work-up. Patients who were
diagnosed with or suspected to have indeterminate colitis,
coexistence of infectious or ischemic colitis, coexistence
of other localized or systemic infections, any malignant
disease, major systemic illness, connective tissue disease,
or inflammatory arthritis were excluded. Patients in the
early therapy arm initiated immunomodulator therapy
(azathioprine or 6-mercaptopurine) within 6 months of
diagnosis. The conventional therapy arm was comprised
of patients with CD who initiated immunomodulatory
therapy more than 6 months after being diagnosed, or
who did not receive immunomodulators during the
course of their disease. The Institutional Review Board of
the Severance Hospital approved this study.
The Crohn’s Disease Activity Index (CDAI) [8], erythro-
cyte sedimentation rate (ESR, normal value <15 mm⁄hr),
C-reactive protein level (CRP, normal value < 8 mg⁄L), and
hematocrit level (Hct, normal value:40.4-52%) were regu-
larly monitored during the follow-up period.Thiopurine dosing and follow-up protocol
The initial azathioprine dose (0.5-1.0 mg/kg) was
increased to 2.0 to 2.5 mg/kg over one- to four-week
intervals unless there were adverse effects. The initial 6-
mercaptopurine (6-MP) dose (0.25-0.5 mg/kg) was
increased in the same fashion to 1.0 to 1.5 mg/kg. Dur-
ing AZA/6-MP therapy, 5-ASA was administered at a
conventional dose (mesalazine 3.0 g/day). Outpatient
visits were scheduled at one- to two-week intervals for
the first month, a visit at two months, and visits every
2–3 months thereafter, according to the patient’s clinical
condition.Definition of treatment response and disease relapse
Clinical remission was defined as a CDAI < 150 and clin-
ical response was defined by a 100 point decrease from
the baseline CDAI score [9]. Steroid-free remission was
defined as maintaining remission for up to 4 weeks after
complete withdrawal of corticosteroids. The definition of
disease relapse was a CDAI >150 points plus a 100-point
increase from CDAI baseline [9].
Primary and secondary outcome measures
The primary outcome measure was the proportion of
patients responsive to treatment at each time point during
a 12-month period. The following secondary outcome
measures were considered: (1) clinical remission rate of
each group, (2) steroid-free clinical remission rate of each
group, (3) disease relapse rate of each group, (4) disease-
related hospitalization rate of each group, and (5) surgical
resection rate of each group.
Statistics
Statistical analyses were performed with SPSS software
(version 18.0 for Windows; SPSS, Inc., Chicago, IL,
USA). Continuous variables were compared using a two-
tailed Student’s t-test and categorical data were compared
using a two-tailed χ2 test or Fisher’ exact test. The clinical
response and disease relapse rates after treatment were
illustrated using Kaplan Meier survival curves for the
grouped factors over the intervention period. Moreover,
we analyzed factors associated with relapse by logistic
regression analysis. P -values <0.05 were considered to
indicate statistical significance.
Results
Baseline patient characteristics
The baseline characteristics of the 168 patients with CD
are listed in Table 1. Of them, 102 patients (81 males,
median age ± SD, and 26.5 ± 11.0 years) were treated
with early immunomodulator therapy and the other 66
patients (57 males, median age ± SD, 30.0 ± 12.3 years)
were treated with conventional therapy. The baseline
characteristics of the patients such as age, sex, location
of disease, disease behavior, and laboratory findings ex-
cept for medications used were not significantly different
between the two groups.
Primary and secondary outcome measures
The median length of follow-up for patients was
27 months (Range, 35 or IQR, 21). The clinical remis-
sion rates at 6 months were 85.0% in the early immuno-
modulator group and 76.4% in the conventional therapy
group, respectively (Figure 1A). There was a statistically
significant difference in the overall remission rate be-
tween the two groups (Log Rank test P =0.043). In
addition, corticosteroid-free clinical remission rates at 6
Table 1 Clinical characteristics of patients with Crohn’s
disease (N = 168)
Characteristics Early immuno-
modulator therapy
Conventional
therapy
P-value
Age, yr, median (IQR) 26.5 (11.0) 30 (12.3) 0.137
Sex, (%) 0.305
Male 81 (79.4) 57 (86.4)
Female 21 (20.6) 9 (13.6)
Activity status at start
medication, (%)
0.474
Remission 7 (6.9) 5 (7.6)
Mild 24 (23.5) 17 (25.8)
Moderate 70 (68.6) 41 (62.1)
Severe 1 (1.0) 3 (4.5)
Location, (%) 0.191
L1 (ileal) 9 (8.8) 2 (3.0)
L2 (colonic) 13 (12.7) 7 (10.6)
L3 (ileocolonic) 16 (15.7) 13 (19.7)
L4 (only upper GI) 0 (0) 3 (4.5)
NA 64 (62.8) 41 (62.2)
Behavior at
diagnosis, (%)
0.651
B1 (non-stricturing,
non-penetrating)
20 (19.6) 14 (21.2)
B2 (stricturing) 10 (9.8) 3 (4.6)
Perianal disease 8 (7.8) 8 (12.1)
NA 64 (62.8) 41 (62.1)
Initial medication, (%) <0.001
Only 5-ASA 54 (52.9) 56 (84.8)
5-ASA with steroids 9 (8.8) 10 (15.2)
Only
immunomodulators
3 (2.9) 0 (0)
Immunomodulators
with 5-ASA
36 (35.3) 0 (0)
CDAI, median (IQR) 263.0 (119.5) 249.2 (117.9) 0.643
BMI, median (IQR) 19.8 (4.7) 18.9 (3.7) 0.141
CRP, median (IQR) 8.1 (39.2) 8.9 (24.8) 0.052
ESR, median (IQR) 54.0 (59.0) 55.0 (52.0) 0.462
Hct, median (IQR) 38.4 (8.6) 37.3 (7.2) 0.905
IQR, inter-quartile range; CDAI, Crohn’s disease activity index; BMI, body mass
index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hct,
hematocrit; NA, not applicable.
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in the early immunomodulator group, respectively, and in
22.7% and 38.6% in the conventional group. This also
reached statistical significance (Log Rank test P =0.035)
(Figure 1B).
In the patients treated with early immunomodulator
therapy, 7.0% relapsed at 12 months. This percentageincreased to 22.3% at 24 months and to 60.9% at
36 months (Figure 2A). In patients treated with conven-
tional therapy the relapse rates at months 12, 24, and 36
were 3.6%, 18.2%, and 68.6%, respectively. There was no
statistical significance in relapse rates between the two
groups (Log Rank test P=0.827) (Figure 2A).
After 12, 24, and 36 months of treatment, surgical resec-
tion was performed in 7.8%, 15.0%, and 37.4% of patients
on early immunomodulator therapy, and in 1.6%, 4.7%,
and 31.8% of patients on conventional therapy, respect-
ively, which was not a statistically significant difference
(Log Rank test P=0.326) (Figure 2B).
There was no difference in the risk of disease-related
hospitalization between the two groups at 12, 24, and
36 months, respectively (13.5%, 21.0%, and 50.0% vs. 1.1%,
6.8%, and 45.7%, Log Rank test P=0.228) (Figure 2C).
Predictive factors related to disease relapse
According to univariate analysis, age, gender, body mass
index (BMI), and disease activity as assessed by CDAI
were not significant predictors of relapse (Table 2). In
the analysis of ESR, CRP, and hematocrit, we selected
cut-off points of 15, 8.0, and 40.4, respectively. Patients
who had higher CRP levels relapsed more frequently
compared with those who had lower CRP levels (odds ra-
tio, 3.000; 95% confidence interval, 1.504–5.983; P< 0.005)
(Table 2). However, there were no significant associations
between disease relapse and ESR or hematocrit (Table 2).
Adverse events and side effects
Eleven patients treated with early immunomodulator ther-
apy experienced adverse events such as abdominal pain,
bone marrow suppression, diarrhea, nausea, edema, and
dermatitis (Table 3). Medication tolerance was very good
overall in the patients on conventional therapy (Table 3).
Early immunomodulator therapy was significantly associ-
ated with the development of an adverse event (P=0.029).
Discussion
For a considerable number of patients, the natural course
of CD has a poor prognosis. Nearly all patients suffer from
symptomatic flares and subsequent complications over a
ten-year period [10]. Traditionally, symptom control was
the principal goal of treatment. The conventional thera-
peutic strategy for CD dictates that medications are
chosen based on the severity of symptoms.
In recent years, however, a change in the treatment
goals for patients with CD has come under intense
discussion. To maintain a good quality of life, and to
keep the patient from suffering any irreversible conse-
quences, very early intensive therapy (immunomodulators
and/or biologics) has been suggested as a top-down treat-
ment strategy [11]. The rationale for such an approach
comes from rheumatology, where early intervention with
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Figure 1 The cumulative probabilities of patients who achieved clinical remission (A), and steroid-free remission (B) between early
immunomodulator therapy and conventional therapy groups.
Kwak et al. BMC Gastroenterology 2014, 14:85 Page 4 of 6
http://www.biomedcentral.com/1471-230X/14/85immunomodulators or biologics is thought to prevent
progressive destruction of joints [12].
There are few studies on the efficacy of early immuno-
modulator therapy in patients with CD, and they report
many differences in clinical outcomes. These studies have
shown that early administration of immunomodulators in
patients with CD resulted in superior clinical outcomes
when compared to conventional therapy, with a compar-
able safety profile [13]. On the contrary, in other studies,
early immunomodulator therapy had no significant impact
on CD course [2,14,15].
D'Haens G et al. found that early immunomodulator
and biologic therapy was more effective than conven-
tional management for induction of remission [5]. Like-
wise, we showed that early immunomodulator therapy
demonstrated a higher rate of remission than conven-
tional therapy, suggesting that early intervention withConventional 
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Figure 2 The cumulative probabilities avoiding disease relapse (A), hosp
therapy and conventional therapy groups.immunomodulators might have much more benefit in
achieving clinical remission than the conventional strat-
egy. Moreover, the steroid-free remission rate was also
significantly higher in the early immunomodulator
group. The maintenance of steroid-free remission is a
major issue and one of the major treatment goals in
these patients.
It is important to consider how long specific treatments
maintain clinical remission when evaluating the effective-
ness of a treatment. In a recent study, administration of
immunomodulative agents within 6 months in CD patients
was no more effective than conventional management in
increasing the duration of clinical remission [14]. Similarly,
in our study, there was no difference in the disease relapse
rate between the two groups. There are some possible ex-
planations for the above results. Most importantly, many of
the patients might have been included in the early therapyTime to surgery
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Table 2 Univariate logistic regression analysis of baseline
factors related to relapse
Valuables OR (95% CI) P-value
Age 0.999 (0.967-1.032) 0.940
Gender Male
Female 0.769 (0.337-1.754) 0.533
BMI 0.980 (0.866-1.109) 0.748
CDAI severity Mild
Moderate 1.957 (0.186-20.614) 0.576
Severe 2.203 (0.222-21.849) 0.500
ESR* > 15 mm/hr 0.745 (0.321-1.727) 0.492
CRP† > 8.0 mg/L 3.000 (1.504-5.983) 0.002
Hct‡ > 40.4% 1.203 (0.622-2.329) 0.583
CDAI, Crohn’s disease activity index; BMI, body mass index; ESR, erythrocyte
sedimentation rate; CRP, C-reactive protein; Hct, hematocrit; *cut-off value, 15;
†cut-off value, 8.0; ‡cut-off value, 40.4.
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of their poor clinical features at the start of treatment. Fur-
thermore, a considerable number of patients with conven-
tional therapy initiated treatment with immunomodulators
as time passed in our study, which was also seen by
D'Haens G et al. [5].
In choosing a treatment, we also should consider the
adverse events and side effects. Early immunomodulator
therapy showed a higher frequency of adverse events in this
study. Because of these problems, it is important to identify
the prognostic factors at the time of diagnosis, and earlier ad-
ministration of immunomodulators should be recommended
in selected CD patients with poor prognostic factors.
Surgical resection rates vary widely over time among
published studies, ranging from 25 to 61% at 5 years in a
recent review [16]. There are a few studies showing that
early use of immunomodulators reduces surgical rates.
For example, Lakatos et al. found that early immunomod-
ulator use was associated with a significantly decreased
time to first surgery in patients with CD [17]. However,
we observed no significant difference in surgery ratesTable 3 Adverse events
Early immuno-
suppressive therapy
Conventional
therapy
P-value
Abdominal
pain
1 –
Bone marrow
failure
4 –
Diarrhea – 1
Nausea and
vomiting
4 –
Edema 1 –
Dermatitis 1 –
Total 11 (10.8) 1 (1.5) 0.029between the two groups (Log Rank test P=0.326). There
are some possible reasons for the differences in surgical
resection rates between these studies. First, the diverse
genetic predisposition of the subjects may be one of the
major factors causing these differences [18]. Second, in
the study by Lakatos et al., patients who had used bio-
logical agents were included in the early treatment group,
which may also play a role. In Korea, biologics were
launched into market very late, and patients are allowed
to use biologics only after the failure of immunomodula-
tors and corticosteroids.
The disease-related hospitalization rates observed in our
study showed no difference between the two groups. Simi-
larly, the AZTEC study investigated by Sans M et al. dem-
onstrated that early use of immunomodulators did not
reduce the disease-related hospitalization rate [19].
Several biomarkers have been evaluated as indicators
of disease activity and predictors of the risk of relapse in
patients with CD who are in remission [20]. CRP has
been reported to be useful in predicting short-term
prognosis and relapse [21-23]. In previous reports, a
high baseline CRP was an independent predictor of
relapse [23,24]. According to our results, patients with a
baseline elevated CRP levels showed a higher relapse
rate. Thus, this could play a role in predicting relapse at
the start of treatment in newly diagnosed CD patients.
So far, nearly all studies on the efficacy of early im-
munomodulator therapy have focused on Caucasians.
However, the clinical features of CD in Asian popula-
tions might be different from that in Caucasians [25].
Some studies investigating Asian populations suggest
that the prognosis might be better in Asians compared
to Western patients [26]. In this respect, this is the first
study from an Asian population, which is one of the
strengths of our study. Another strength of this study is
that we demonstrate the efficacy and safety of early im-
munomodulator therapy in CD patients from a clinical
practice setting. Patients encountered in real clinical
practice often differ from those included in registra-
tional trials. The former have a more heterogeneous
mix of patients with co-morbidities and often have
poorer treatment adherence than the latter. Thus, it is
necessary to analyze the data from real clinical practice
to confirm treatment efficacy.
The major limitation of our study is that it was a
retrospective, observational study, which had the poten-
tial for selection bias and confounding factors. Another
limitation comes from the small size of the studied
population, which necessitates further prospective stud-
ies with a large number of patients.
Conclusion
In conclusion, our study found that early immunomodula-
tor therapy was more efficient than conventional therapy
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immunomodulator therapy failed to maintain clinical
remission and adverse events were significantly more
frequent. Given the findings that there was no difference
in disease relapse, need for surgery, or hospitalization, and
that adverse events were more frequent in early immu-
nomodulator therapy, we cannot assert that early im-
munomodulator therapy is unequivocally better than
conventional therapy. Therefore, we should evaluate
whether patients have poor prognostic factors at base-
line. Then, early immunomodulator therapy could be
selectively applied.
Competing interests
No potential conflict of interest relevant to this article was reported.
Authors’ contributions
MSK and JHC contributed to the conception and design of the study. DHK,
SJP, TIK, SPH, and WHK were responsible for acquisition, analysis and
interpretation of data. MSK and JHC drafted the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This study was supported by a grant (2013-E63004-00) from the Research of
Korea Centers for Disease Control and Prevention and a grant of the Korean
Health Technology R&D Project, Ministry of Health & Welfare, Republic of
Korea (grant number A120176).
Author details
1Department of Internal Medicine, Graduate School, Yonsei University
College of Medicine, Seoul, Korea. 2Department of Internal Medicine and
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul,
Korea. 3Department of Internal Medicine, Yonsei University College of
Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
Received: 6 February 2014 Accepted: 28 April 2014
Published: 3 May 2014
References
1. Ling KL, Chuah SW, Kong SC: Healing the mucosa in Crohn's disease: does
it matter? Singap Med J 2013, 54(4):185–189.
2. Fascì Spurio F, Aratari A, Margagnoni G, Doddato MT, Papi C: Early
treatment in Crohn's disease: do we have enough evidence to reverse
the therapeutic pyramid? J Gastrointestin Liver Dis 2012, 21(1):67–73.
3. Eugene C: The second European evidence-based consensus on the
diagnosis and management of Crohn's disease (part 4). Clin Res Hepatol
Gastroenterol 2011, 35(8–9):518–520.
4. Cosnes J, Nion Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP:
Impact of the increasing use of immunosuppressants in Crohn's disease
on the need for intestinal surgery. Gut 2005, 54(2):237–241.
5. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H,
De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ,
Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van
Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D,
Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut
Club: Early combined immunosuppression or conventional management
in patients with newly diagnosed Crohn's disease: an open randomised
trial. Lancet (London, England) 2008, 371(9613):660–667.
6. Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the
treatment of inflammatory bowel disease: a 30 year review. Gut 2002,
50(4):485–489.
7. Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J
Gastroenterol Suppl 1989, 170:2–6.
8. Best WR, Becktel JM, Singleton JW: Rederived values of the eight
coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology
1979, 77(4):843–846.
9. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M,
Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G,Travis S, Stange E, European Crohn's and Colitis Organisation (ECCO): The
second European evidence-based Consensus on the diagnosis and
management of Crohn's disease: Definitions and diagnosis. J Crohns
Colitis 2010, 4(1):7–27.
10. Munkholm P, Langholz E, Davidsen M, Binder V: Disease activity courses in
a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995,
30(7):699–706.
11. Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F: Clinical prognostic
factors for disabling Crohn's disease: a systematic review and
meta-analysis. World J Gastroenterol 2013, 19(24):3866–3871.
12. Kirwan JR: Conceptual issues in scoring radiographic progression in
rheumatoid arthritis. J Rheumatol 1999, 26(3):720–725.
13. Punati J, Markowitz J, Lerer T, Hyams J, Kugathasan S, Griffiths A, Otley A,
Rosh J, Pfefferkorn M, Mack D, Evans J, Bousvaros A, Moyer MS, Wyllie R,
Oliva-Hemker M, Mezoff A, Leleiko N, Keljo D, Crandall W, Pediatric IBD
Collaborative Research Group: Effect of early immunomodulator use in
moderate to severe pediatric Crohn disease. Inflamm Bowel Dis 2008,
14(7):949–954.
14. Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M,
Dupas J-L, Reimund J-M, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF,
Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube
Digestif (GETAID): Early administration of azathioprine vs conventional
management of Crohn's disease: a randomized controlled trial.
Gastroenterology 2013, 145(4):758–765.
15. Panés J, López-SanRomán A, Bermejo F, García-Sánchez V, Esteve M, Torres
Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans
M, AZTEC Study Group: Early azathioprine therapy is no more effective
than placebo for newly diagnosed Crohn’s disease. Gastroenterology 2013,
145(4):766–774.
16. Wolters FL, Russel MG, Stockbrügger RW: Systematic review: has disease
outcome in Crohn's disease changed during the last four decades?
Aliment Pharmacol Ther 2004, 20(5):483–496.
17. Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T,
Erdelyi Z, Gemela O, Papp J, Lakatos L: Perianal disease, small bowel
disease, smoking, prior steroid or early azathioprine/biological therapy
are predictors of disease behavior change in patients with Crohn's
disease. World J Gastroenterol 2009, 15(28):3504–3510.
18. Kim ES, Kim WH: Inflammatory bowel disease in Korea: epidemiological,
genomic, clinical, and therapeutic characteristics. Gut Liver 2010, 4(1):1–14.
19. Sans M, López-San Román A, Esteve M, Bermejo F, García-Sánchez V, Torres Y,
Domenech E, Piqueras M, Aceituno M, Gomez-Garcia M, Taxonera C, Gisbert JP:
Early use of azathioprine Has a steroid sparing effect on recently diagnosed
Crohn's disease patients. Gastroenterology 2011, 140(5):S-109.
20. Desai D, Faubion WA, Sandborn WJ: Review article: biological activity
markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007,
25(3):247–255.
21. Reinisch W, Wang Y, Oddens BJ, Link R: C-reactive protein, an indicator for
maintained response or remission to infliximab in patients with Crohn's
disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012,
35(5):568–576.
22. Consigny Y, Modigliani R, Colombel J, Dupas J, Lémann M, Mary J: A simple
biological score for predicting low risk of short-term relapse in Crohn's
disease. Inflamm Bowel Dis 2006, 12(7):551–557.
23. Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B: C-reactive protein
levels during a relapse of Crohn's disease are associated with the clinical
course of the disease. World J Gastroenterol 2008, 14(1):85–89.
24. Bitton A, Dobkin PL, Edwardes MD, Sewitch MJ, Meddings JB, Rawal S,
Cohen A, Vermeire S, Dufresne L, Franchimont D, Wild GE: Predicting
relapse in Crohn's disease: a biopsychosocial model. Gut 2008,
57(10):1386–1392.
25. Ahuja V, Tandon RK: Inflammatory bowel disease in the Asia-Pacific area:
a comparison with developed countries and regional differences. J Dig
Dis 2010, 11(3):134–147.
26. Ye BD, Yang S, Cho YK, Park SH, Yang D, Yoon SM, Kim KJ, Byeon J, Myung
S, Yu CS, Kim JH: Clinical features and long-term prognosis of Crohn's
disease in Korea. Scand J Gastroenterol 2010, 45(10):1178–1185.
doi:10.1186/1471-230X-14-85
Cite this article as: Kwak et al.: Efficacy of early immunomodulator
therapy on the outcomes of Crohn’s disease. BMC Gastroenterology
2014 14:85.
